FDA Approves Brixadi for Medication-Assisted Treatment
The U.S. Food and Drug Administration (FDA) has approved BRIXADI, also known as buprenorphine, for people with moderate to severe opioid use disorder. The drug is an extended-release injection for subcutaneous use (CIII), meant to be taken weekly or monthly at a healthcare provider’s office. Brixadi is a form of Medication-Assisted Treatment meant to help
